Radient Technologies Inc. (TSX Venture:RTI) is pleased to provide an update on its manufacturing facility expansion, pending ACMPR license, and future growth initiatives in Europe.
Expansion of Manufacturing Capacity
Further to its previously announced expansion plans, the capacity expansion of Radient’s existing manufacturing facility is now nearing completion, with construction expected to be completed by the end of June 2018. The expansion provides a new processing line dedicated exclusively to intermediate and end-use products using extracted THC, and makes use of a number of new innovations in Radient’s proprietary extraction platform. Commissioning of the expanded facility is anticipated through the summer of 2018. As previously announced, Radient recently acquired two parcels of land adjacent to the facility, providing more than 80,000 sq. ft. of additional real estate for subsequent future capacity expansions and additions to Radient’s extraction and product development capabilities.
Cannabis Extraction Operations
Radient’s manufacturing facility (including the expansion) is located approximately 20 kilometers from the Aurora Sky facility owned by Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) (OTCQB:ACBFF) (Frankfurt: 21P; WKN: A1C4WM), and approximately 575 Kilometres from the site in southern Alberta where the Aurora Sun facility is being built. Aurora holds an approximately 17% ownership interest in Radient, and in November 2017, the companies entered into a Master Services Agreement (“MSA”) for the extraction of cannabinoids. Aurora has recently announced its intention to acquire MedReleaf Corp., which upon completion will create a global cannabis company with 570,000 kg per annum in funded capacity in Canada and the EU. The MedReleaf acquisition, upon completion, is expected to be accretive to Radient, as the new combination will require significant additional extraction capacity as can be delivered by Radient through its high throughput technology.
ACMPR License from Health Canada
The Company is in the final review stages of its application to Health Canada’s Office of Medical Cannabis for a production license for the expanded facility under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). Approval of the ACMPR license is dependent upon, among other things, Health Canada’s review of recorded security footage of the expansion, to be submitted after construction of the expansion is completed. The Company anticipates receiving its ACMPR license from Health Canada by early Q4 2018. Additionally, the Company’s application to the Office of Controlled Substances for a Dealer’s License for the expanded facility is currently under review. The Company also anticipates receiving its Dealer’s License for the expanded facility from Health Canada by early Q4 2018.
The Company received its Dealer’s License from Health Canada’s Office of Controlled Substances for its research & development laboratory located at 8223 Roper Road in February 2018 (see Radient’s news release dated February 5, 2018).
Expansion Initiatives in Europe
With the market value for legal cannabis in Europe forecast at over CAD $85 billion (source: Prohibition PartnersEuropean Cannabis Report: 2nd Edition), and new medical cannabis laws having been passed recently in Germany, Italy, Poland, Greece, and the Czech Republic, Radient is finalizing initiatives with respect to expanding its business operations into the European Union. These initiatives include site identification, preliminary design work, detailed capacity planning, technology selection, and initial capital costing.
Denis Taschuk, President & CEO of Radient stated: “Radient has experienced incredible growth over the last year, and we realize the potential that the burgeoning cannabis sectors in Canada and further abroad present as countries continue to legalize the use of medical cannabis. Radient looks forward to working closely with its partners to expand its footprint into Europe in the coming months.”
About Radient
Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health and personal care markets. Since 2016, Radient has expanded its offerings to enter the cannabinoids market utilizing its MAP™ platform to process and extract cannabinoids including cannabidiol and tetrahydrocannabinol from cannabis biomass. Visit www.radientinc.com for more information.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
Read Next
